Although PPAR?? agonists such as rosiglitazone and pioglitasone improve insulin resistance and glucose tolerance in obese mice models, previous studies also have shown that inhibition of PPAR?? signaling significantly improve metabolic disorders including obesity, dyslipidemia, and diabetes [20, 22].